Relypsa Announces Presentation of New Clinical and Real-World Analyses of Veltassa® at AMCP Nexus 2018
22 oct. 2018 08h00 HE
|
Relypsa, Inc.
REDWOOD CITY, Calif., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Relypsa, Inc., a Vifor Pharma Group company, will present new data on Veltassa® (patiromer) at the Academy of Managed Care Pharmacy’s AMCP...
Relypsa Announces Presentation of New Clinical and Real-World Analyses of Veltassa® at ASN Kidney Week 2018
09 oct. 2018 16h00 HE
|
Relypsa, Inc.
REDWOOD CITY, Calif., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Relypsa, Inc., a Vifor Pharma Group company, will present new data on Veltassa® (patiromer) at the American Society of Nephrology (ASN) Kidney...
Relypsa Announces Appointment of Patrick Treanor as President
01 oct. 2018 08h00 HE
|
Relypsa, Inc.
REDWOOD CITY, Calif., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Relypsa, Inc., a Vifor Pharma Group company, today announced the appointment of Patrick Treanor as president on an interim basis, effective...
Relypsa Announces FDA Approval of Supplemental New Drug Application to Enable the Usage of Veltassa® (patiromer) With or Without Food
08 mai 2018 08h00 HE
|
Relypsa, Inc.
REDWOOD CITY, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- Relypsa, Inc., a Vifor Pharma Group company, today announced that the United States (U.S) Food and Drug Administration (FDA) approved a...
Relypsa Funds Three Innovative Research Projects on Hyperkalemia and Associated Disorders
16 avr. 2018 16h00 HE
|
Relypsa, Inc.
REDWOOD CITY, Calif., April 16, 2018 (GLOBE NEWSWIRE) -- Relypsa, Inc., a Vifor Pharma Group company, today announced that it has awarded three research grants to supplement institutional funding...
Relypsa Presents Patiromer Clinical Trial Data on Serum Potassium in Patients with Hyperkalemia at the National Kidney Foundation 2018 Spring Clinical Meetings
11 avr. 2018 08h00 HE
|
Relypsa, Inc.
REDWOOD CITY, Calif., April 11, 2018 (GLOBE NEWSWIRE) -- Relypsa, Inc., a Vifor Pharma Group company, today announced results from a pooled analysis of three clinical trials evaluating the effects...
Relypsa Announces Presentation of New Clinical and Real-World Analyses of Veltassa® at ASN Kidney Week 2017
03 nov. 2017 17h30 HE
|
Relypsa, Inc.
REDWOOD CITY, Calif., Nov. 03, 2017 (GLOBE NEWSWIRE) -- Relypsa, Inc., a Vifor Pharma Group company, today announced results from a prespecified analysis of data from the Phase 4 TOURMALINE study of...
Relypsa Announces European Approval of Veltassa® to Treat Adult Patients with Hyperkalemia (Elevated Blood Potassium Levels)
21 juil. 2017 08h00 HE
|
Relypsa, Inc.
Today’s European Commission approval is the second worldwide; in the U.S., more than 33,000 patients have been treated with Veltassa since it was approved by the FDA in 2015Patients with advanced...
Relypsa Presents Veltassa® Phase 4 Data Showing Consistent Efficacy and Safety Whether Taken With or Without Food in Patients with Hyperkalemia
19 avr. 2017 18h00 HE
|
Relypsa, Inc.
In the study, Veltassa, the first new medicine approved by the FDA for hyperkalemia in more than 50 years, showed a consistent potassium-lowering effect and safety profile whether taken with or...
Relypsa Announces Publication of Results of Veltassa Drug-Drug Interaction Studies in Journal of Cardiovascular Pharmacology and Therapeutics
13 févr. 2017 16h30 HE
|
Relypsa, Inc.
Phase 1 studies with 12 oral medications commonly used in hyperkalemic patients with chronic kidney disease showed minimal risk for drug-drug interactions with Veltassa when other oral drugs are...